pioglitazone and Depressive Disorder

pioglitazone has been researched along with Depressive Disorder in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in HDRS-21: From Baseline to 12 Weeks

The HDRS-21 was administered at baseline and at the end of 12 weeks, and the mean difference between the two time points was calculated. The HDRS-21 is scored on a scale from 0 to 21, where 0 is the lowest level of depression severity and 21 is the highest level of depression severity. (NCT01559857)
Timeframe: 12 weeks

Fasting Insulin Measurements at Baseline

The fasting plasma insulin measurements taken at baseline are shown in the data table below. (NCT01559857)
Timeframe: Baseline

Hamilton Depression Rating Scale at Baseline

The HDRS-21 was used to screen for unremitted depression. The HDRS-21 is scored on a scale from 0 to 21, where 0 is the lowest level of depression severity and 21 is the highest level of depression severity. Unremitted depression is characterized by a score of ≥7. The HDRS-21 scores at baseline are shown in the data table below. (NCT01559857)
Timeframe: Baseline

Trials

1 trial available for pioglitazone and Depressive Disorder